Diagnosis and management of clostridium difficile infection

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 10, 2013, Pages 1216-1223

  DuPont, Herbert L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic associated Diarrhea; Clostridium difficile Infection; Fidaxomicin; Metronidazole; Microbiome; Oral Vancomycin

Indexed keywords

ANTITOXIN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B ANTIBODY; FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; SUROTOMYCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIOTHERAPY; CELL ASSAY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENZYME IMMUNOASSAY; EXPERIMENTAL THERAPY; FALSE POSITIVE RESULT; FECAL TRANSPLANTATION; FECES ANALYSIS; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INTESTINE FLORA; METAGENOMICS; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRACTICE GUIDELINE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REPEATED DRUG DOSE; SACCHAROMYCES BOULARDII; SIGMOIDOSCOPY; TREATMENT DURATION;

ANTIBIOTIC-ASSOCIATED DIARRHEA; CDI; CLOSTRIDIUM DIFFICILE INFECTION; FIDAXOMICIN; GDH; GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; MICROBIOME; NAP1; NORTH AMERICAN PULSE-FIELD TYPE 1; ORAL VANCOMYCIN; POSITIVE PREDICTIVE VALUE; PPV; REAL-TIME POLYMERASE CHAIN REACTION; RT-PCR;

ADMINISTRATION, ORAL; AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOTHERAPY; METRONIDAZOLE; MOLECULAR DIAGNOSTIC TECHNIQUES; VANCOMYCIN;

EID: 84884350794     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.016     Document Type: Article

References (87)

1. Khan M.Y., Hall W.H. Staphylococcal enterocolitis-treatment with oral vancomycin. Ann Intern Med 1966, 65:1-8.
2. Tedesco F.J., Stanley R.J., Alpers D.H. Diagnostic features of clindamycin-associated pseudomembranous colitis. N Engl J Med 1974, 290:841-843.
3. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia. N Engl J Med 1978, 298:531-534.
4. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
5. Ananthakrishnan A.N., McGinley E.L., Saeian K., et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:976-983.
6. Deshpande A., Pasupuleti V., Patel P., et al. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. Curr Med Res Opin 2012, 28:1553-1560.
7. Samore M.H., DeGirolami P.C., Tlucko A., et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994, 18:181-187.
8. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320:204-210.
9. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
10. Sharp S.E., Ruden L.O., Pohl J.C., et al. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol 2010, 48:2082-2086.
11. Deshpande A., Pasupuleti V., Rolston D.D., et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011, 53:e81-e90.
12. Longtin Y., Trottier S., Brochu G., et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013, 56:67-73.
13. Vaishnavi C., Bhasin D., Kochhar R., et al. Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes Infect 2000, 2:1827-1830.
14. Deshpande A., Pasupuleti V., Patel P., et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011, 9:665-669.
15. Belmares J., Johnson S., Parada J.P., et al. Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis 2009, 49:1141-1147.
16. Bergstein J.M., Kramer A., Wittman D.H., et al. Pseudomembranous colitis: how useful is endoscopy?. Surg Endosc 1990, 4:217-219.
17. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
18. Valiquette L., Pépin J., Do X.V., et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis 2009, 49:554-560.
19. Wenisch J.M., Schmid D., Kuo H.W., et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis 2012, 31:1923-1930.
20. Chung H., Kasper D.L. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol 2010, 22:455-460.
21. Turroni F., Ribbera A., Foroni E., et al. Human gut microbiota and bifidobacteria: from composition to functionality. Antonie Van Leeuwenhoek 2008, 94:35-50.
22. Harpe S.E., Inocencio T.J., Pakyz A.L., et al. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship. Pharmacotherapy 2012, 32:744-754.
23. Bien J., Palagani V., Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?. Ther Adv Gastroenterol 2013, 6:53-68.
24. Zwielehner J., Lassl C., Hippe B., et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS ONE 2011, 6:e28654.
25. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993, 17:109-113.
26. Gorschlüter M., Ziske C., Glasmacher A., et al. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clin Cancer Res 2001, 7:2195-2204.
27. Kamboj M., Son C., Cantu S., et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012, 33:1162-1165.
28. Trifilio S.M., Pi J., Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:405-409.
29. Wardill H.R., Bowen J.M., Gibson R.J. Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. Cancer Chemother Pharmacol 2012, 70:627-635.
30. Navaneethan U., Mukewar S., Venkatesh P.G., et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis 2012, 6:330-336.
31. Armstrong D., Rytina E.R., Murphy G.M., et al. Gastric mucosal toxicity of duodenal juice constituents in the rat. Acute studies using ex vivo rat gastric chamber model. Dig Dis Sci 1994, 39:327-339.
32. Jenkins G.J., Harries K., Doak S.H., et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004, 25:317-323.
33. Wallace J.L., Syer S., Denou E., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011, 141. 1314-1322.e1-5.
34. Bavishi C., DuPont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34:1269-1281.
35. Deshpande A., Pant C., Pasupuleti V., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:225-233.
36. DuPont H.L., Jiang Z.D., Okhuysen P.C., et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005, 142:805-812.
37. Louie T.J., Emery J., Krulicki W., et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009, 53:261-263.
38. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342:390-397.
39. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
40. Jiang Z.D., Garey K.W., Price M., et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 2007, 5:964-968.
41. Garey K.W., Jiang Z.D., Ghantoji S., et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010, 51:1406-1410.
42. Katchar K., Taylor C.P., Tummala S., et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol 2007, 5:707-713.
43. Mullane K.M., Miller M.A., Weiss K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other Concurrent infections. Clin Infect Dis 2011, 53:440-447.
44. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
45. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
46. Bolton R.P., Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986, 27:1169-1172.
47. Johnson S., Homann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117:297-302.
48. Keighley M.R., Burdon D.W., Arabi Y., et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 1978, 2:1667-1669.
49. Mogg G.A., Arabi Y., Youngs D., et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980, 22(Suppl):41-45.
50. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis. Lancet 1983, 2:1043-1046.
51. Pépin J., Routhier S., Gagnon S., et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006, 42:758-764.
52. Garey K.W., Ghantoji S.S., Shah D.N., et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011, 66:2850-2855.
53. Johnson S., Schriever C., Patel U., et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15:290-291.
54. Kasper A.M., Nyazee H.A., Yokoe D.S., et al. A multicenter study of Clostridium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol 2012, 33:470-476.
55. Lamontagne F., Labbé A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007, 245:267-272.
56. Neal M.D., Alverdy J.C., Hall D.E., et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011, 254:423-427. discussion 7-9.
57. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic?. Clin Infect Dis 2008, 46:1493-1498.
58. Pepin J., Valiquette L., Gagnon S., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007, 102:2781-2788.
59. Brandt L.J., Borody T.J., Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe Clostridium difficile infection?. J Clin Gastroenterol 2011, 45:655-657.
60. Brandt L.J., Reddy S.S. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011, 45(Suppl):S159-S167.
61. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
62. Hamilton M.J., Weingarden A.R., Sadowsky M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:761-767.
63. Silverman M.S., Davis I., Pillai D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010, 8:471-473.
64. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:1079-1087.
65. Jiang Z.D., Hoang L.N., Lasco T.M., et al. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis 2013, 56:1059-1060.
66. Dendukuri N., Costa V., McGregor M., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005, 173:167-170.
67. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 2009, 30:826-833.
68. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010, 16:2202-2222.
69. Pozzoni P., Riva A., Bellatorre A.G., et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012, 107:922-931.
70. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
71. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
72. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335:80.
73. Enache-Angoulvant A., Hennequin C. Invasive saccharomyces infection: a comprehensive review. Clin Infect Dis 2005, 41:1559-1568.
74. Lherm T., Monet C., Nougière B., et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28:797-801.
75. Salminen M.K., Tynkkynen S., Rautelin H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002, 35:1155-1160.
76. Allen-Vercoe E., Reid G., Viner N., et al. A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 2012, 26:457-462.
77. Petrof E.O., Gloor G.B., Vanner S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePooPulating" the gut. Microbiome 2013, 1:1-12.
78. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004, 53:882-884.
79. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997, 41:366-370.
80. Shahani L., Koirala J. Intravenous immunoglobulin in treatment of Clostridium difficile colitis. BMJ Case reports 2012 May 8, Epub ahead of print.
81. Aldeyab M.A., McElnay J.C., Scott M.G., et al. An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections. Infect Control Hosp Epidemiol 2011, 32:631-633.
82. Juang P., Skledar S.J., Zgheib N.K., et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007, 35:131-137.
83. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
84. Giannasca P.J., Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004, 22:848-856.
85. Kyne L., Kelly C.P. Prospects for a vaccine for Clostridium difficile. BioDrugs 1998, 10:173-181.
86. Sougioultzis S., Kyne L., Drudy D., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128:764-770.
87. Lee B.Y., Popovich M.J., Tian Y., et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010, 28:5245-5253.